Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial is a research paper published in Seminars in Thoracic and Cardiovascular Surgery (2022). On theSindex it has a DataRank of 0.241. It has been cited 4 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Heart, Lung, and Blood Institute
Grant: F30HL154324
National Center for Advancing Translational Sciences
Grant: UL1TR001855
NCATS NIH HHS
Grant: UL1 TR000130
National Institutes of Health
FWCI
0.54
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals